Sees FY23 adjusted EBITDA of $10M-$12M.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst Reports Third Quarter 2023 Results
- Health Catalyst Acquires ERS, Bolsters Tech-Enabled Managed Services Offering with Data Abstraction and Oncology Registry Management Capabilities
- Health Catalyst price target lowered to $8 from $13 at RBC Capital
- Health Catalyst sees 2023 revenue $291M-$296M, consensus $293.78M
- Health Catalyst sees Q4 revenue $70.1M-$75.1M, consensus $73.96M